| Heading: |
Drugs: Artificial Intelligence |
| Question ID: |
1796544 |
| UIN: |
HL6785 |
| House: |
Lords |
| Date tabled: |
2025-04-23 |
| Asking Member ID: |
2593 |
| Asking Member display name: |
Lord Freyberg
|
| Asking Member handle: |
|
| Asking Member Twitter reference: |
Lord Freyberg
|
| Member interest: |
false |
| Question text: |
To ask His Majesty's Government what assessment they have made of the use of AI-integrated health monitoring tools to manage unsupervised use of medications such as semaglutide. |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-05-01 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
347 |
| Answering Member display name: |
Baroness Merron
|
| Answering Member handle: |
|
| Answering Member Twitter reference: |
Baroness Merron
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
Currently, no assessment has been made on the use of artificial intelligence (AI) to monitor the unsupervised use of these medications. However, we recognise the potential of AI and monitoring systems to support people’s health and care, including through... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |